Wanlong Wu, Runci Wang, Cuiying Xie, Yi Chen, Xiangyu Teng, Shuhui Sun, Wenwen Xu, Yakai Fu, Yiyangzi Ma, Antao Xu, Xia Lyu, Yan Ye, Jia Li, Chunyan Zhang, Nan Shen, Xiaodong Wang, Shuang Ye, Qiong Fu
BACKGROUND: Data with fine granularity about COVID-19-related outcomes and risk factors were still limited in the idiopathic inflammatory myopathies (IIMs) population. This study aimed to investigate clinical factors associated with hospitalized and severe COVID-19 in patients with IIMs, particularly those gauged by myositis-specific antibodies. METHODS: This retrospective cohort study was conducted in the Renji IIM cohort in Shanghai, China, under an upsurge of SARS-CoV-2 omicron variant infections from December 2022 to January 2023...
2024: Frontiers in Immunology